CMS moved ahead with a restrictive coverage-with-evidence-development policy for a long-used chronic back pain therapy over the protests of product stakeholders and broader device industry interests who worry about the precedent it sets.
The agency issued its final national coverage decision memo for transcutaneous electrical nerve stimulation for treating chronic back pain June 8, sticking with the basic approach laid out...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?